ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 32
| Issue : 4 | Page : 1382-1387 |
|
Comparing the efficacy of cefixime versus amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women
Emad Eldeen Soliman, Mohamed A Emara, Abdelhamid E Shahin, Mahmoud A M Nafie
Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Correspondence Address:
Mahmoud A M Nafie Shebin El-Kom, Menoufia Governorate Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_304_18
|
|
Objective
To evaluate efficacy of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria (ASB) in pregnant women.
Background
ASB can cause progressive and severe infections and endanger maternal as well as fetal health. Bacteriuria is usually associated with low birth weight, high blood pressure during pregnancy, maternal anemia, and fetal death.
Patients and methods
A prospective randomized study was conducted on 100 pregnant women having ASB in the first and early second trimester attending the pregnancy follow-up clinic in Galaa Teaching Hospital. Detailed history, laboratory investigations, obstetric, and ultrasound follow-up study were done.
Results
Maternal age (year) of patients ranged from 20 to 35 years, with a mean of 26.06 ± 4.91 years. The presence of pus and serial assessments of fetal growth were significant differences among the studied patients. Overall, 25% of patients had Intrauterine growth retardation (IUGR), 13% had premature rupture of membranes, and 13% had preterm labor. Adverse effects of drug such as presence of Gastrointestinal (GIT) upset, diarrhea, and vaginal candida infection were significantly increased in group 1 (18, 22, and 22%, respectively) than group 2 (4, 6, and 6%, respectively).
Conclusion
The use of amoxicillin/clavulanate is significantly more often accompanied by the development of adverse reactions compared with cefixime. Amoxicillin/clavulanate shows higher incidence of GIT manifestation, diarrhea, and vaginal candida infection. So, further larger studies could provide cost-benefit data necessary to inform a national screening program.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|